account_id none on file
legal_name Oncolytics Biotech Inc
ticker ONCY
cik 1129928
domain oncolyticsbiotech.com
linkedin_company_url https://www.linkedin.com/company/oncolytics-biotech-inc./
entry_point_account_id none on file
name Oncolytics Biotech Inc.
exchange Nasdaq
sector Health Care
hq San Diego, CA, United States
sector index/company/sector/health-care/
calls 0 filings 1 executives 1 family 0
why_nownone on file
callsnone on file
filings
• Increased personnel-related expenses due to increased stock-based compensation expense and increased headcount. The increase in stock-based compensation expense was due to new stock option grants in the second half of 2025 and an adjustment to reclassify options from equity-classified to liability classified as discussed in note 3 of the condensed consolidated financial statements.
filing / May 14, 2026 / receipt
executives
| John McAdory | Executive Vice President, Strategy and Operations | - | receipt |
familynone on file
upcoming
| 2026-11-11 | earnings call | scheduled | ir |
changes
| 2026-06-02 | Chief Operating Officer, appointed | sec_8k |
mcp_package_hint
slug oncolytics-biotech-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$